🇺🇸 BMS-650032 (Asunaprevir) in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8

Most-reported reactions

1. Alanine Aminotransferase Increased — 1 report (12.5%)
2. Aspartate Aminotransferase Increased — 1 report (12.5%)
3. Blood Bilirubin Increased — 1 report (12.5%)
4. Decreased Appetite — 1 report (12.5%)
5. Fatigue — 1 report (12.5%)
6. Hypersomnia — 1 report (12.5%)
7. Nausea — 1 report (12.5%)
8. Somnolence — 1 report (12.5%)

Source database →

Frequently asked questions

Is BMS-650032 (Asunaprevir) approved in United States?

BMS-650032 (Asunaprevir) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for BMS-650032 (Asunaprevir) in United States?

Bristol-Myers Squibb is the originator. The local marketing authorisation holder may differ — check the official source linked above.